A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

Lingfang Xia; Qi Zhou; Yunong Gao; Wenjing Hu; Ge Lou; Hong Sun; Jianqing Zhu; Jin Shu; Xianfeng Zhou; Rong Sun; Xiaohua Wu

doi:10.1038/s41467-022-35133-4

Nature Communications (Dec 2022)

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

Lingfang Xia,
Qi Zhou,
Yunong Gao,
Wenjing Hu,
Ge Lou,
Hong Sun,
Jianqing Zhu,
Jin Shu,
Xianfeng Zhou,
Rong Sun,
Xiaohua Wu

Affiliations

Lingfang Xia: Department of Gynecological Oncology, Fudan University Shanghai Cancer Center
Qi Zhou: Department of Gynaecology, Affiliated Tumor Hospital of Chongqing University
Yunong Gao: Department of Gynaecology, Beijing Cancer Hospital
Wenjing Hu: Department of Oncology, Nanjing Drum Tower Hospital
Ge Lou: Department of Gynaecology, Affiliated Tumor Hospital of Harbin Medical University
Hong Sun: Department of Gynecologic Oncology, Obstetrics & Gynecology Hospital of Fudan University
Jianqing Zhu: Department of Gynecological Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Jin Shu: Department of Gynaecology, Affiliated Tumor Hospital of Chongqing University
Xianfeng Zhou: Department of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Rong Sun: Department of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Xiaohua Wu: Department of Gynecological Oncology, Fudan University Shanghai Cancer Center

DOI: https://doi.org/10.1038/s41467-022-35133-4
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

Patients with recurrent or metastatic cervical cancer have limited therapeutic options. Here the authors report efficacy and safety of camrelizumab (anti-PD-1 antibody) in combination with famitinib (anti-angiogenic agent) in pre-treated recurrent or metastatic squamous cervical cancer.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal